NLRP3 and hepatocellular carcinoma: Activation of NLRP3 can drive an inflammatory response, while inhibition of NLRP3 may aggravate immune exhaustion in patients with advanced HCC, which is not conducive to ICIs treatment and leads to poor efficacy of ICIs treatment in patients in the high-risk group [56,57,58].